Quantus

TOMOCUBE

A475960 · KOSDAQ
₩32,500+9.80%
2026-08-03 close
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 26.78
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
26.78
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
-4.04%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -110%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-147.8%
Interest coverage
-133.3x
Return on equity (ROE)
-19.8%

Operating margin −5pp

Operating loss
Interest coverageBase -133.3x adverse case -137.8x
Return on equity (ROE)Base -19.8% adverse case -21.8%

Revenue −15%

Interest coverage risk
Interest coverageBase -133.3x adverse case -113.3x
Return on equity (ROE)Base -19.8% adverse case -17.9%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -133.3x adverse case -89.4x
Return on equity (ROE)Base -19.8% adverse case -21.1%

Interest coverage limit

Already below the limit by 149pp

Interest coverage limit at an operating margin of 1.1%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-20

Suppliers disclosed by the company in its 2026-03-20 annual report.

Suppliers without disclosed amount

XYZUSDMIX

Financials at a glance

TOMOCUBE's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 박용근27.34%2026-05-28 · 증감 -0.04%p
  • 인터베스트13.27%2024-11-12 · 증감 +13.27%p

Connections

AI-extracted related companies · for reference

Competitors
ZeissNikonOlympusLeica MicrosystemsThermo Fisher ScientificDanaher
Same theme
Zeiss3D cell cultureorgan-on-a-chip
🔗 See in the full market map →

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ 1억(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Recent filings

TOMOCUBE's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

New MA alignment×3
26-04-17-20.2%26-04-01-2.4%26-03-26-9.1%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy